Sign in
← Compounds

AOD-9604

peptide · headlineResearch use only

Stimulates lipolysis

Summary

AOD-9604 is a modified peptide fragment of human growth hormone designed to stimulate fat metabolism while avoiding the adverse effects associated with hGH therapy. It promotes lipolysis, inhibits fat formation, and has a proven safety profile in human studies. It has been explored in clinical research for obesity and metabolic modulation.

How it works

  • Stimulates lipolysis
  • Inhibits lipogenesis
  • Mimics metabolic region of hGH without affecting IGF-1 levels

Dosing

  • unit: mcg
    low dose: 400
    frequency: Once daily
    high dose: 600
    standard dose: 500
    administration route: Subcutaneous (SQ)
  • unit: mg
    low dose: 0.5
    frequency: Once daily
    high dose: 1.5
    standard dose: 1
    administration route: Oral

Cycling

  • Inject 500 mcg in the morning while fasted. Cycle 20 days on, 10 days off, or up to 12 weeks with 2-week break. Effects build gradually; consistent use required for best outcomes.

Side effects

long term: ["Development terminated in 2007 — larger Phase IIb trial (536 subjects, 24 weeks) failed to achieve statistical significance; drug not FDA-approved"]

Chemistry & PK

sequence: Tyr-hGH177-191
half life: Approximately 4 hours
degradation: Metabolized by proteolytic enzymes in peripheral tissue
molecular weight: 1813.1
molecular formula: C112H179N29O35S
tissue specificity: Primarily targets adipose tissue; also shows chondrocyte activation in cartilage

Verified citations

2 · PubMed-checked

Used for

No condition evidence rows yet.

Legal / compounding

Research use only

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.